"We're enjoying the one-two punch," Mark Goldsmith, president and CEO of Revolution Medicines Inc., told BioWorld after the Redwood City, Calif.-based firm inked an oncology partnership with Sanofi SA covering its SHP2 program. In return for an exclusive license for global commercialization of any approved products targeting SHP2, the Paris-based pharma agreed to provide Revolution with $50 million up front and up to $500 million in development and regulatory milestone payments and to fund R&D for the joint SHP2 program, which remains, for now, under Revolution's direction.